Tarsus Pharmaceuticals, Inc. (CIK: 0001819790) EDGAR, Information, Filings... CompaniesBIO.Com

Tarsus Pharmaceuticals, Inc.

Mailing address
15440 LAGUNA CANYON ROAD, IRVINE, Delaware, 92618
Phone
(949) 409-9820
State location
California
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Filings
N/A

Tarsus Pharmaceuticals, Inc. (CIK: 0001819790) is an American company incorporated in the state of California. Head office is located at 15440 LAGUNA CANYON ROAD, IRVINE, California, 92618. Work in the industry 2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES). Tarsus Pharmaceuticals, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Farrow Jeffrey S	0001405253	Apr-24-2023	officer: See Remarks
Trevejo Jose M.	0001661539	Mar-08-2023	officer: Chief Medical Officer
Morrison Scott W	0001662426	Oct-06-2022	director
Lin Elizabeth Yeu	0001842190	Dec-31-2021	director
Crane Rosemary A	0001443343	Aug-11-2021	director
Wahl Bryan	0001841401	Jan-19-2021	officer: General Counsel
Whitfield Dianne C.	0001839516	Jan-07-2021	officer: Chief Human Resources Officer
YARNO WENDY L	0001181186	Nov-19-2020	director
RTW INVESTMENTS, LP	0001493215	Oct-16-2020	10 percent owner
WONG RODERICK	0001493280	Oct-16-2020	10 percent owner
LINK WILLIAM J PHD	0001228684	Oct-15-2020	director
Topper James N	0001341382	Oct-15-2020	10 percent owner
Heron Patrick J	0001365617	Oct-15-2020	10 percent owner
CHAUDHURI BHASKAR	0001458643	Oct-15-2020	director
Greenstein Leonard M.	0001519692	Oct-15-2020	officer: Chief Financial Officer
Frazier Life Sciences IX, L.P.	0001720320	Oct-15-2020	10 percent owner
Vivo Capital Fund IX, L.P.	0001750117	Oct-15-2020	10 percent owner
Vivo Capital IX, LLC	0001750698	Oct-15-2020	10 percent owner
FHMLS IX, L.P.	0001782789	Oct-15-2020	10 percent owner
FHMLS IX, L.L.C.	0001782791	Oct-15-2020	10 percent owner
Mottiwala Aziz	0001788542	Oct-15-2020	officer: Chief Commercial Officer
Ackermann Michael	0001791249	Oct-15-2020	director, 10 percent owner
Tester Jason E.	0001827272	Oct-15-2020	director, 10 percent owner
Holdbrook Mark J.	0001827564	Oct-15-2020	officer: V.P., Clinical Affairs
Neervannan Seshadri	0001827584	Oct-15-2020	officer: Chief Operating Officer
Azamian Bobak R.	0001827672	Oct-15-2020	director, 10 percent owner, officer: President and CEO
Goldberg Andrew D.	0001827722	Oct-15-2020	director
Horowitz Limited Partnership VIII	0001827839	Oct-15-2020	10 percent owner

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Tarsus Pharmaceuticals, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000113 ( Act) Size: 0 KB	Sep-17-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-097097 ( Act) Size: 0 KB	Aug-14-2024
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001961863-24-000244 (33 Act) Size: 0 KB	Aug-12-2024	001-39614 241197137
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001819790-24-000111 (34 Act) Size: KB	Aug-08-2024	001-39614 241188492
8-K	Document	Current report filing Acc-no: 0001819790-24-000109 (34 Act) Size: KB	Aug-08-2024	001-39614 241188279
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000104 ( Act) Size: 0 KB	Jun-25-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000103 ( Act) Size: 0 KB	Jun-25-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000102 ( Act) Size: 0 KB	Jun-25-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000100 ( Act) Size: 0 KB	Jun-25-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000099 ( Act) Size: 0 KB	Jun-25-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000098 ( Act) Size: 0 KB	Jun-25-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000097 ( Act) Size: 0 KB	Jun-25-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000089 ( Act) Size: 0 KB	Jun-20-2024
8-K	Document	Current report filing Acc-no: 0001819790-24-000087 (34 Act) Size: KB	Jun-18-2024	001-39614 241052202
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001959173-24-004524 (33 Act) Size: 0 KB	Jun-18-2024	001-39614 241051702
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000085 ( Act) Size: 0 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000083 ( Act) Size: 0 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000081 ( Act) Size: 0 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000079 ( Act) Size: 0 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001819790-24-000077 ( Act) Size: 0 KB	Jun-14-2024

Recent 20 filings. View all Tarsus Pharmaceuticals, Inc. filings

Overall rating 5.0

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Tarsus Pharmaceuticals, Inc. overview
Tarsus Pharmaceuticals, Inc. job
Tarsus Pharmaceuticals, Inc. stock
Tarsus Pharmaceuticals, Inc. ownership
Tarsus Pharmaceuticals, Inc. CEO
Tarsus Pharmaceuticals, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.